Too much of a good thing? Participants taking the highest dose of Eli Lilly’s new GLP-1 drug lost an average of 28.7% of their body weight in a late-stage trial, putting it on track to be a ...

One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of ...

Eli Lilly’s Q4 beat and bullish 2026 guidance highlight GLP-1 strength from Mounjaro/Zepbound, supporting a $1240–1300 target. Click here to read more.

Eli Lilly (LLY) Q4 revenue jumped 43% to $19.3B. Mounjaro sales surged 110% to $7.4B. Novo Nordisk (NVO) expects sales to decline 5% to 13% in 2026 due to pricing pressures and patent losses. Lilly’s ...

Arizona-based Strive Compounding Pharmacy has sued Eli Lilly (LLY) and Novo Nordisk (NVO) in a Texas federal court alleging that the drug giants coordinated to stifle competition by hindering access ...

Eli Lilly's stock trades at more than 30 times forward earnings, which is a steep price to pay right now. Amgen is a much cheaper option by comparison. It also has a promising GLP-1 treatment in ...